DURECT Stock Forecast, Price & News

+0.02 (+1.19 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.16 million shs
Average Volume1.53 million shs
Market Capitalization$386.59 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.



DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.57 out of 5 stars

Medical Sector

485th out of 2,100 stocks

Pharmaceutical Preparations Industry

236th out of 830 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

DURECT (NASDAQ:DRRX) Frequently Asked Questions

Is DURECT a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DURECT stock.
View analyst ratings for DURECT
or view top-rated stocks.

What stocks does MarketBeat like better than DURECT?

Wall Street analysts have given DURECT a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but DURECT wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is DURECT's next earnings date?

DURECT is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for DURECT

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) announced its quarterly earnings data on Tuesday, May, 4th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.05). The specialty pharmaceutical company had revenue of $2.21 million for the quarter, compared to analyst estimates of $2.63 million. DURECT had a negative net margin of 2.33% and a negative trailing twelve-month return on equity of 28.91%.
View DURECT's earnings history

How has DURECT's stock price been impacted by COVID-19 (Coronavirus)?

DURECT's stock was trading at $1.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DRRX shares have increased by 3.0% and is now trading at $1.70.
View which stocks have been most impacted by COVID-19

What price target have analysts set for DRRX?

6 equities research analysts have issued 12-month target prices for DURECT's shares. Their forecasts range from $5.00 to $8.00. On average, they expect DURECT's share price to reach $6.60 in the next year. This suggests a possible upside of 288.2% from the stock's current price.
View analysts' price targets for DURECT
or view top-rated stocks among Wall Street analysts.

Who are DURECT's key executives?

DURECT's management team includes the following people:
  • Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 64, Pay $775.88k)
  • Mr. Michael H. Arenberg, CFO & Sec. (Age 51, Pay $452.94k)
  • Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 64, Pay $406.51k)
  • Dr. Norman L. Sussman, Chief Medical Officer (Age 68, Pay $419.68k)
  • Dr. Andrew R. Miksztal, VP of Pharmaceutical R&D and Principal Scientist
  • Mr. Steve Helmer J.D., VP & Chief Patent Counsel
  • Dr. WeiQi Lin, Exec. VP of R&D and Principal Scientist
  • Ms. Jian Li M.B.A., VP of Fin. & Corp. Controller (Age 51)
  • Dr. Su Il Yum, Exec. Officer (Age 82)

Who are some of DURECT's key competitors?

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by many different institutional and retail investors. Top institutional shareholders include Lion Point Capital LP (6.73%), BlackRock Inc. (6.51%), Lion Point Capital LP (5.65%), Ingalls & Snyder LLC (3.27%), JPMorgan Chase & Co. (1.85%) and Renaissance Technologies LLC (1.72%). Company insiders that own DURECT stock include First Eagle Investment Managem, Judy R Joice and Lp Bleichroeder.
View institutional ownership trends for DURECT

Which institutional investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including Lion Point Capital LP, Lion Point Capital LP, Renaissance Technologies LLC, Morgan Stanley, Squarepoint Ops LLC, Beirne Wealth Consulting Services LLC, AQR Capital Management LLC, and Credit Suisse AG. Company insiders that have sold DURECT company stock in the last year include Judy R Joice, and Lp Bleichroeder.
View insider buying and selling activity for DURECT
or view top insider-selling stocks.

Which institutional investors are buying DURECT stock?

DRRX stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Millennium Management LLC, Dimensional Fund Advisors LP, BlackRock Inc., Geode Capital Management LLC, Goldman Sachs Group Inc., Cambridge Investment Research Advisors Inc., and Barclays PLC. Company insiders that have bought DURECT stock in the last two years include First Eagle Investment Managem, and Lp Bleichroeder.
View insider buying and selling activity for DURECT
or or view top insider-buying stocks.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $1.70.

How much money does DURECT make?

DURECT has a market capitalization of $386.59 million and generates $30.11 million in revenue each year. The specialty pharmaceutical company earns $-580,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

How many employees does DURECT have?

DURECT employs 81 workers across the globe.

What is DURECT's official website?

The official website for DURECT is

Where are DURECT's headquarters?

DURECT is headquartered at 10260 BUBB RD, CUPERTINO CA, 95014.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417 or via email at [email protected]

This page was last updated on 6/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.